Teriparatide is a recombinant form of parathyroid hormone (PTH). Teriparatide is identical to a portion of human PTH and intermittent use activates osteoblasts more than osteoclasts, which leads to an overall increase in bone. This makes it an effective anabolic, i.e. bone growing, agent. It is therefore used for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women.

Daewon signed a licensing agreement with Richter-Helm BioTec, which is a joint venture between Hungary-based Gedeon Richter and Germany’s Helm, to sell Terrosa in South Korea in February 2017. Daewon then received marketing approval from South Korea’s drug regulator, the Ministry of Food and Drug Safety (MFDS), for Terrosa in November 2019 [1].

Terrosa is the first biosimilar of teriparatide to be launched in Korea and the first biological marketed by Daewon. According to the company, ‘the treatment has not only proved its effectiveness and safety but also has excellent price competitiveness, which will likely reduce the burden on patients’.

According to Daewon, the local osteoporosis treatment market has one million patients and is worth about Won 200 billion (US$162.5 million). The injection market for osteoporosis treatment is also estimated at Won 70 billion.

Related articles
Teriparatide biosimilar Terrosa launched in Europe

Biosimilars of teriparatide

Biosimilars approved in South Korea

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Teriparatide biosimilar Terossa approved in South Korea [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Jun 19]. Available from: www.gabionline.net/Biosimilars/News/Teriparatide-biosimilar-Terossa-approved-in-South-Korea

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. 

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.